Nidhi Shashikumar is a data scientist and business intelligence expert with over 7 years of experience in healthcare ...

In the latest trading session, Gilead Sciences (GILD) closed at $106.67, marking a -0.38% move from the previous day. The stock fell short of the S&P 500, which registered a gain of 1.77% for the day.

The San Francisco Business Times and its sister publications in Sacramento and San Jose are assembling key thinkers and ...

The head of the U.N. AIDS agency says the sudden loss of American money has been “devastating” for efforts to stop HIV and ...

RBC Capital analyst Brian Abrahams maintained a Hold rating on Gilead Sciences (GILD – Research Report) today and set a price target of $90.00.

Gilead Sciences sees strong growth in HIV & oncology with BIKTARVY & TRODELVY. Learn about upcoming drugs & market potential ...

Spring is a great time to get outside and start taking care of your health, which is exactly why the Wellness Council of ...

A single shot of a new formulation of the antiretroviral drug lenacapavir could potentially provide protection against HIV ...

Ovarian cancer (OC) is the fifth most common cause of cancer-related mortality worldwide and represents the leading cause of death for gynecological malignancies. Nevertheless, over the last years, ...

A single shot of a new formulation of the antiretroviral drug lenacapavir could potentially provide protection against HIV infection for as long as a year. Spotlight reports on this and some of the ...

OSU Marion graduate, Mount Gilead native Kaitlynn Pfeifer accepted into mock in vitro fertilization lab in North Carolina.

Mount Gilead and Gilead Township will go forward with plans for a 23-acre solar installation following its approval by the ...